Eyegene Inc.
Records under this name other than the patents Eyegene Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 8 of 8 · Back to Eyegene Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,897,739 | Method for diagnosing diabetic retinopathy by single nucleotide polymorphism, DNA fragment thereof, and primer thereof Term ended Term ended Dec 28, 2025 · From the USPTO record | Term ended | Term ended Dec 28, 2025 | From the USPTO record |
| US 9,572,877 | Vaccine for inducing an improved immune reaction Lapsed on the fee record Ended Feb 21, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 21, 2025 | From the USPTO record |
| US 10,918,709 | Immune modulator and vaccine composition containing the same Lapsed on the fee record Ended Feb 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 16, 2025 | From the USPTO record |
| US 9,566,323 | Vaccine for cervical cancer Lapsed on the fee record Ended Feb 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 14, 2025 | From the USPTO record |
| US 8,372,811 | Composition for treating retinopathy or glaucoma comprising thrombin derived peptides Lapsed on the fee record Ended Feb 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 12, 2025 | From the USPTO record |
| US 7,507,802 | Immune stimulating and controlling composition comprising bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides Term ended Term ended Dec 12, 2023 · From the USPTO record | Term ended | Term ended Dec 12, 2023 | From the USPTO record |
| US 8,883,987 | Immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides Term ended Ended no later than Sep 26, 2022 · From the USPTO record | Term ended | Ended no later than Sep 26, 2022 | From the USPTO record |
| US 9,101,581 | Method for treating vascular-related disease Surrendered on reissue Surrendered on reissue Jun 2, 2020 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Jun 2, 2020 | From the USPTO record |